Desh Rakshak Aushdhalaya Past Earnings Performance
Past criteria checks 4/6
Desh Rakshak Aushdhalaya has been growing earnings at an average annual rate of 7%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 2.5% per year. Desh Rakshak Aushdhalaya's return on equity is 5.5%, and it has net margins of 8.4%.
Key information
7.0%
Earnings growth rate
6.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 2.5% |
| Return on equity | 5.5% |
| Net Margin | 8.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Desh Rakshak Aushdhalaya makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 63 | 5 | 9 | 0 |
| 30 Jun 24 | 60 | 4 | 8 | 0 |
| 31 Mar 24 | 60 | 4 | 8 | 0 |
| 31 Dec 23 | 52 | 4 | 8 | 0 |
| 30 Sep 23 | 61 | 5 | 8 | 0 |
| 30 Jun 23 | 60 | 4 | 8 | 0 |
| 31 Mar 23 | 62 | 4 | 8 | 0 |
| 31 Dec 22 | 65 | 4 | 10 | 0 |
| 30 Sep 22 | 56 | 4 | 10 | 0 |
| 30 Jun 22 | 62 | 5 | 10 | 0 |
| 31 Mar 22 | 62 | 5 | 10 | 0 |
| 31 Dec 21 | 73 | 5 | 9 | 0 |
| 30 Sep 21 | 72 | 4 | 10 | 0 |
| 30 Jun 21 | 70 | 4 | 10 | 0 |
| 31 Mar 21 | 66 | 4 | 10 | 0 |
| 31 Dec 20 | 55 | 3 | 10 | 0 |
| 30 Sep 20 | 51 | 3 | 9 | 0 |
| 30 Jun 20 | 50 | 3 | 9 | 0 |
| 31 Mar 20 | 51 | 3 | 9 | 0 |
| 31 Dec 19 | 51 | 3 | 9 | 0 |
| 30 Sep 19 | 52 | 3 | 8 | 0 |
| 30 Jun 19 | 52 | 3 | 9 | 0 |
| 31 Mar 19 | 55 | 3 | 9 | 0 |
| 31 Dec 18 | 53 | 4 | 9 | 0 |
| 30 Sep 18 | 54 | 3 | 9 | 0 |
| 30 Jun 18 | 51 | 3 | 8 | 0 |
| 31 Mar 18 | 51 | 3 | 7 | 0 |
| 31 Dec 17 | 49 | 4 | 8 | 0 |
| 30 Sep 17 | 45 | 3 | 7 | 0 |
| 30 Jun 17 | 51 | 3 | 7 | 0 |
| 31 Mar 17 | 51 | 3 | 8 | 0 |
| 31 Dec 16 | 45 | 2 | 6 | 0 |
| 30 Sep 16 | 54 | 4 | 9 | 0 |
| 30 Jun 16 | 53 | 3 | 9 | 0 |
| 31 Mar 16 | 49 | 3 | 7 | 0 |
| 31 Dec 15 | 52 | 1 | 8 | 0 |
| 30 Sep 15 | 45 | 0 | 8 | 0 |
| 30 Jun 15 | 43 | 0 | 6 | 0 |
| 31 Mar 15 | 43 | 0 | 6 | 0 |
| 31 Dec 14 | 39 | 1 | 12 | 0 |
| 30 Sep 14 | 34 | 1 | 12 | 0 |
| 30 Jun 14 | 39 | 1 | 6 | 0 |
| 31 Mar 14 | 39 | 1 | 12 | 0 |
| 31 Dec 13 | 43 | 0 | 11 | 0 |
Quality Earnings: 531521 has high quality earnings.
Growing Profit Margin: 531521's current net profit margins (8.4%) are higher than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531521's earnings have grown by 7% per year over the past 5 years.
Accelerating Growth: 531521's earnings growth over the past year (18.5%) exceeds its 5-year average (7% per year).
Earnings vs Industry: 531521 earnings growth over the past year (18.5%) did not outperform the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 531521's Return on Equity (5.5%) is considered low.